Show simple item record

dc.contributor.authorNeto, Fani L.
dc.contributor.authorBorges, Gisela
dc.contributor.authorTorres-Sanchez, Sonia
dc.contributor.authorMicó, Juan Antonio
dc.contributor.authorBerrocoso, Esther
dc.contributor.otherMedicinaen_US
dc.contributor.otherMedicinaen_US
dc.contributor.otherPsicologíaen_US
dc.date.accessioned2015-11-19T11:24:21Z
dc.date.available2015-11-19T11:24:21Z
dc.date.issued2011-01-01T00:00:00Z
dc.identifier.otherPMID: 22654714
dc.identifier.urihttp://hdl.handle.net/10498/17886
dc.description.abstractDepression is a neuropsychiatric disorder affecting a huge percentage of the active population especially in developed countries. Research has devoted much of its attention to this problematic and many drugs have been developed and are currently prescribed to treat this pathology. Yet, many patients are refractory to the available therapeutic drugs, which mainly act by increasing the levels of the monoamines serotonin and noradrenaline in the synaptic cleft. Even in the cases antidepressants are effective, it is usually observed a delay of a few weeks between the onset of treatment and remission of the clinical symptoms. Additionally, many of these patients who show remission with antidepressant therapy present a relapse of depression upon treatment cessation. Thus research has focused on other possible molecular targets, besides monoamines, underlying depression. Both basic and clinical evidence indicates that depression is associated with several structural and neurochemical changes where the levels of neurotrophins, particularly of brain-derived neurotrophic factor (BDNF), are altered. Antidepressants, as well as other therapeutic strategies, seem to restore these levels. Neuronal atrophy, mostly detected in limbic structures that regulate mood and cognition, like the hippocampus, is observed in depressed patients and in animal behavioural paradigms for depression. Moreover, chronic antidepressant treatment enhances adult hippocampal neurogenesis, supporting the notion that this event underlies antidepressants effects. Here we review some of the preclinical and clinical studies, aimed at disclosing the role of neurotrophins in the pathophysiological mechanisms of depression and the mode of action of antidepressants, which favour the neurotrophic/neurogenic hypothesis.en_US
dc.formatapplication/pdfen_US
dc.language.isoengen_US
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.sourceCurr Neuropharmacol. 2011 Dec;9(4):530-52.en_US
dc.subjectAntidepressantsen_US
dc.subjectBDNFen_US
dc.subjectdepressionen_US
dc.subjecthippocampalen_US
dc.subjectneurogenesisen_US
dc.subjectneuropsychiatric disordersen_US
dc.subjectstressen_US
dc.subjectVal66Met polymorphismen_US
dc.subjectVGFen_US
dc.titleNeurotrophins Role in Depression Neurobiology: A Review of Basic and Clinical Evidenceen_US
dc.typeinfo:eu-repo/semantics/articleen_US
dc.rights.accessRightsinfo:eu-repo/semantics/openAccessen_US
dc.identifier.doi10.2174/157015911798376262
dc.identifier.doi10.2174/157015911798376262


Files in this item

This item appears in the following Collection(s)

Show simple item record

Attribution-NonCommercial-NoDerivatives 4.0 Internacional
This work is under a Creative Commons License Attribution-NonCommercial-NoDerivatives 4.0 Internacional